**7. Conclusion**

Tricuspid valve used to be a "forgotten" valve in terms of hemodynamic consequences and appropriate time of surgery. Still, there is no ideal valve substitute for tricuspid valve replacement in cases of severe leaflet damage when valve repair is not feasible. A variety of challenging circumstances and unresolved issues exist in the treatment of tricuspid valve disease, which encourages us to find alternative solution in such clinical scenarios like active infective endocarditis, prosthetic endocarditis, and dysfunction where commonly used prosthetic material does not seem to be perfect. Assuming our initial experience with mitral homograft for tricuspid valve replacement, allograft tissue valves might take place as a plausible valve substitute, especially in patients with endocarditis, either native or prosthetic. Excellent hemodynamic performance along with highly acceptable clinical results could be achieved with mitral homografts in tricuspid surgery according to the results of our study. Low risk of perioperative complications, zero early and mid-term mortality, as well as no need for redo surgery in one postoperative year allow us to consider mitral homograft as an alternative substitute to the biological and mechanical prosthesis in tricuspid valve surgery.
